Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Strong-Buy at Redburn Atlantic

Key Points

• Regeneron Pharmaceuticals has received a new rating of "strong-buy" from Redburn Atlantic, indicating heightened analyst confidence in the stock.
• Several analysts have adjusted their price targets for Regeneron, with BMO Capital Markets raising it from $600 to $640, while Truist Financial lowered it from $940 to $812.
• Following its recent earnings report, Regeneron reported a quarterly EPS of $12.89, significantly higher than analysts' estimates of $8.43, demonstrating strong financial performance.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by equities researchers at Redburn Atlantic to a "strong-buy" rating in a report issued on Thursday,Zacks.com reports.

A number of other equities research analysts also recently commented on REGN. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $838.00.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $565.97 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The stock has a fifty day moving average price of $542.46 and a 200 day moving average price of $596.26. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a market cap of $59.99 billion, a PE ratio of 14.26, a P/E/G ratio of 1.90 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The company had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the company earned $11.56 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Adirondack Trust Co. grew its stake in Regeneron Pharmaceuticals by 4.2% during the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 18 shares during the last quarter. Kingswood Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after buying an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV grew its stake in Regeneron Pharmaceuticals by 9.5% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after buying an additional 19 shares during the last quarter. Private Trust Co. NA grew its stake in Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 19 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its stake in Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after buying an additional 19 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.